Hershey offers concession to Reese's family member with ingredient changes

Hershey reiterated FY26 guidance and expects 15%–20% EPS growth in FY27. Following public accusations from a Reese's heir, the company plans ingredient changes (including swapping a chocolate compound coating by 2027), KitKat recipe enhancements, a shift to natural colors, and a 25% increase in R&D to support product changes and expansion into snacks. The PR controversy drove a near-term stock dip but shares remain up ~14% YTD; Stifel keeps a Hold rating citing premium valuation despite expected margin restoration and earnings growth.

Analysis

The incident has become a branding event more than an operations one: social amplification can convert a localized product tweak into a measurable shortfall in trial and repeat purchase within days. Expect a near-term sales elasticity shock concentrated in formats with high SKU churn (seasonal minis, limited editions) where trial rates are highest; a 1–3 percentage-point national share swing in the confection category over one quarter is plausible if retailers amplify promotions.

Second-order supply effects matter and are underpriced by consensus: any broad move to “cleaner” inputs or colorants re-routes incremental spend away from commodity intermediates into niche suppliers (annatto/curcumin, specialized emulsifiers), creating pockets of input inflation even as headline cocoa cycles normalize. That bifurcation compresses short-term gross margin unless price realization is immediate; margins can diverge by 100–250bps across SKUs depending on scale and packaging complexity.

Key catalysts to watch are weekly point-of-sale scan data and 3rd-party blind taste results—these will move volumes within 1–12 weeks and set the path for whether management can monetize reformulation via pricing. Tail risks: sustained consumer backlash or a credible governance campaign could inflict multi-quarter volume declines; conversely, rapid positive blind-taste outcomes plus commodity tailwinds can restore margins and produce outsized returns for patient holders within 6–12 months.

Key Decisions for Investors

• Pair trade (3–12 months): Long MDLZ / Short HSY, dollar neutral. Entry signal: HSY underperforms MDLZ by >200 bps relative over 5 trading days or HSY gaps down >7% on headlines. Target: capture 6–12% relative move; stop if pair divergence reverses by 6%.
• Event-driven long (6–12 months): Add HSY on headline-driven pullback >8% from today, size 1–2% portfolio. Rationale: if scan/taste data normalizes and commodity tailwinds persist, expect 12–20% upside; hard stop at -12% to limit reputational-driven downside.
• Options hedge (9 months): Buy HSY 10% OTM puts and finance with sale of 30% OTM calls (collar). Cost-profile: protection begins at -10% with upside capped beyond +30%; suitable for existing long exposure to limit downside for <2% annualized cost.
• Consumer retail tactical (0–3 months): Overweight grocers/private-label beneficiaries (e.g., KR, WMT) by rotation size 0.5–1% portfolio to capture short-term trade-down and promotional flow. Expect 3–7% relative outperformance in the first quarter post-incident; cut if branded sales re-accelerate on taste/PR wins.